How to Value a Dermatology Group (Multi-Location PE Platform)

Single-location dermatology practices and multi-location dermatology platforms are valued in fundamentally different ways. I've advised on both, and the gap in valuations is staggering. A solo dermatologist selling their practice might get 4-6x EBITDA from a health system or another physician. A 5+ location platform with professional management, multiple providers, and a cosmetic revenue stream? That's a 10-16x EBITDA asset that PE firms fight over. Understanding what separates a practice from a platform — and how to position for platform-level multiples — is worth millions.

Why PE Loves Dermatology

Private equity has poured capital into dermatology for a decade, and the thesis hasn't changed because the fundamentals haven't changed. Dermatology has structural advantages that most medical specialties lack: procedures are primarily outpatient (no hospital overhead), reimbursement has remained relatively stable compared to primary care, the cosmetic revenue stream is cash-pay with no insurance friction, and the aging U.S. population drives steadily growing demand for skin cancer screening and treatment.

The fragmentation is what makes it a PE target. There are roughly 12,000 practicing dermatologists in the U.S., and the majority still operate in 1-3 provider practices. PE firms see the same opportunity they executed in dental (DSOs), ophthalmology, and veterinary: buy a platform, bolt on smaller practices, centralize back-office operations, and sell the consolidated entity at a higher multiple than they paid for the pieces.

Named platforms tell the story. Schweiger Dermatology Group (backed by Centerbridge Partners) has grown to 100+ locations. Forefront Dermatology (backed by Partners Group) operates 200+ clinics. Advanced Dermatology and Cosmetic Surgery (acquired by Dr. Phillip Frost, then later by various PE sponsors) built a national footprint. U.S. Dermatology Partners, QualDerm Partners, Pinnacle Dermatology — the list of PE-backed platforms keeps growing because the model works.

Platform Multiples: 10-16x EBITDA

The multiple range for dermatology platforms depends on scale, management infrastructure, and growth trajectory. Here's how the market segments in 2026:

• 5-10 locations, $3-8M EBITDA: 10-12x EBITDA. This is the emerging platform stage. You have enough scale to be interesting but haven't fully proven the centralized management model.
• 10-25 locations, $8-20M EBITDA: 12-14x EBITDA. The proven platform. You have a management team, a repeatable bolt-on acquisition playbook, and a track record of integration.
• 25+ locations, $20M+ EBITDA: 14-16x EBITDA. Institutional scale. Multiple PE firms will compete for this asset. The buyer is purchasing a platform that can absorb acquisitions without missing a beat.

These multiples are applied to adjusted EBITDA, which in dermatology means adding back fair market value physician compensation adjustments, one-time costs, and above-market rent on owned real estate. The adjustments matter enormously — I've seen EBITDA adjustments swing a dermatology platform's valuation by 20-30%.

What Drives Premium Multiples

Provider count and composition. A platform with 20 providers across 8 locations is more valuable than one with 8 providers across 8 locations, even at similar revenue. More providers means less key-person risk and more capacity for growth. The composition matters too: board-certified dermatologists are the core, but Mohs surgeons and dermatopathologists command disproportionate value because they drive high-margin procedural revenue.

Mohs surgery volume. Mohs micrographic surgery for skin cancer is one of the highest-reimbursed procedures in dermatology. A platform with 3-4 fellowship-trained Mohs surgeons generating $1.5-2M per surgeon in annual collections is sitting on a premium asset. PE buyers specifically model Mohs capacity in their valuation because the reimbursement is favorable and the demand is growing with the aging population.

Cosmetic revenue as a percentage of total. This is where the real premium lives. A dermatology practice that generates 30-40% of revenue from cosmetic services — Botox, fillers, laser treatments, CoolSculpting, chemical peels — is worth meaningfully more than a pure medical derm practice. Cosmetic revenue is cash-pay, has higher margins, is less subject to reimbursement cuts, and demonstrates that the practice has built a consumer brand. I've seen the cosmetic revenue mix add 1-2 turns of EBITDA multiple.

Same-store growth. PE buyers distinguish between growth from acquisitions and organic same-store growth. A platform showing 8-12% same-store revenue growth demonstrates that the model works independent of M&A. If your growth is entirely from bolt-ons with flat or declining same-store performance, buyers will discount the multiple because they question the sustainability.

Mid-Level Provider Leverage

The ability to extend capacity through physician assistants and nurse practitioners is a critical value driver for derm platforms. A dermatologist who supervises 2-3 PAs/NPs each seeing 25-30 patients per day generates significantly more revenue per physician than a solo practitioner seeing 35 patients personally. The economics are compelling: a PA in dermatology generates $400,000-$600,000 in annual collections at a compensation cost of $130,000-$170,000.

PE buyers love mid-level leverage because it's the primary organic growth lever post-acquisition. They can recruit PAs and NPs more easily than board-certified dermatologists (the residency pipeline produces only ~700 new dermatologists per year nationally), and the economics scale favorably. A platform with a strong mid-level program — standardized training, supervision protocols, and a track record of successful PA/NP integration — commands a premium.

The regulatory landscape matters here. States vary significantly in nurse practitioner scope of practice for dermatological procedures. Platforms operating in states with favorable supervision requirements (like Arizona or Oregon) can leverage mid-levels more aggressively than those in restrictive states, and buyers model this into their geographic expansion plans.

Geographic Density and the Cluster Strategy

The most successful derm platforms aren't geographically scattered — they're built in clusters. A platform with 10 locations within a 50-mile radius is worth more than one with 10 locations across 5 states. Density enables shared management, cross-referrals between locations, efficient marketing spend, and a single credentialing and compliance infrastructure.

Schweiger Dermatology's strategy in the New York metro illustrates this perfectly — dense geographic coverage that creates a referral network and a brand that patients recognize across the region. PE buyers model the value of density because it directly impacts EBITDA margins: a 10-location platform in one metro typically runs 300-500 basis points better margins than the same 10 locations spread across multiple states.

The Second Bite: PE Recapitalization

This is where the real wealth creation happens for physician-owners in PE-backed platforms. The "second bite of the apple" occurs when the PE sponsor sells the platform to a new PE buyer after 4-6 years of growth. Because the platform has grown through acquisitions and operational improvements, it sells at a higher EBITDA and a higher multiple than the initial investment.

The math is powerful. A physician who sold their 3-location practice at 8x EBITDA to a PE-backed platform and rolled 30% of their equity into the platform might see that rolled equity return 3-5x on the recapitalization. In dollar terms: a physician who received $5M at closing and rolled $1.5M in equity could see that $1.5M become $4.5-$7.5M at the recap. The second check is often larger than the first.

This dynamic has become a key selling point for PE-backed platforms recruiting new practices. Forefront Dermatology's recent transactions and Schweiger's growth have demonstrated the model to the broader derm community. If you're evaluating whether to sell to a PE-backed platform versus a health system, the second-bite opportunity is the single biggest differentiator.

Management Infrastructure: The Platform Premium

What separates a platform from a collection of practices is management infrastructure. PE buyers will pay a premium for a derm group that has a non-physician CEO or COO, a centralized billing and coding operation, standardized EMR across all locations, a dedicated HR function, and a proven bolt-on acquisition process. These elements prove that the business can operate and grow independently of any single physician.

I've seen derm groups with identical revenue and EBITDA receive valuations that differ by 3-4x turns of EBITDA based entirely on management maturity. A group where the founding dermatologist still manages the billing, hires the staff, and negotiates the leases is a practice. A group where those functions are handled by professional management is a platform. The transition from practice to platform is what unlocks the 10x+ multiples.

The Bottom Line

Multi-location dermatology platforms represent one of the most attractive physician practice models in healthcare M&A. The combination of stable medical reimbursement, high-margin cosmetic revenue, mid-level leverage, and PE appetite creates a valuation environment where well-built platforms command 10-16x EBITDA. The key is building genuine platform infrastructure — not just opening locations, but creating the management systems, provider pipeline, and geographic density that PE buyers will pay a premium for. If you're already running a multi-location derm group, the difference between a 8x and a 14x exit is in the details of how you build the business over the next 2-3 years.